pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

35 catalysts · 11 phase 2 completion · 9 phase 1 completion · 5 phase 1 initiation · 5 phase 2 initiation · 3 phase 3 initiation · 1 phase 0 trial completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 11 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: immunology×clear all
type
  • phase 2 completion11
  • phase 1 completion9
  • phase 1 initiation5
  • phase 2 initiation5
  • phase 3 initiation3
  • phase 0 trial completion1
phase iv trial initiation
1
therapy area
  • Oncology148
  • Infectious Disease46
  • Cardiology37
  • Immunology35
  • Dermatology31
  • Pulmonology22
  • Women's Health19
  • Ophthalmology16
  • Pain15

Week of Apr 20, 2026

10
›Apr 24, 2026phase 1 initiation91d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

full page →CMSD-001 →source: globaldata
›Apr 24, 2026phase 2 completion91d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

full page →lixudebart →source: globaldata
›Apr 24, 2026phase iv trial initiation91d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

full page →melatonin →source: globaldata
›Apr 25, 2026phase 1 completion90d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

full page →YTS-109 →source: globaldata
›Apr 25, 2026phase 2 completion90d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

full page →Himani fast relief gel →source: globaldata
›Apr 25, 2026phase 2 initiation90d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →bifidobacterium →source: globaldata
›Apr 25, 2026phase 3 initiation90d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →olokizumab →source: globaldata
›Apr 26, 2026phase 2 completion89d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

full page →decidual stromal cells →source: globaldata
›Apr 26, 2026phase 2 initiation89d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

full page →DICLOFENAC SODIUM →source: globaldata
›Apr 26, 2026phase 3 initiation89d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

full page →zanubrutinib →source: globaldata

Week of Apr 27, 2026

25
›Apr 27, 2026phase 1 completion88d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

Therapy area: Immunology. Indication: Unspecified Immunological Disorders

full page →PTC-844 →source: globaldata
›Apr 27, 2026phase 1 completion
88d ago
Fortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

full page →balinatunfib →source: globaldata
›Apr 27, 2026phase 1 initiation88d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

Therapy area: Immunology. Indication: Liver Transplant Rejection

full page →fostamatinib →source: globaldata
›Apr 27, 2026phase 3 initiation88d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →abatacept →source: globaldata
›Apr 28, 2026phase 1 initiation87d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

full page →BW-20805 →source: globaldata
›Apr 28, 2026phase 1 initiation87d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

full page →HN-2302 →source: globaldata
›Apr 28, 2026phase 2 completion87d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

full page →albumin gel- and platelet- rich fibrin →source: globaldata
›Apr 28, 2026phase 2 initiation87d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

full page →dexamethasone acetate →source: globaldata
›Apr 29, 2026phase 2 initiation86d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

Therapy area: Immunology. Indication: Kidney Transplant Rejection

full page →siplizumab →source: globaldata
›Apr 29, 2026phase 2 initiation86d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

full page →KK-4277 →source: globaldata
›Apr 30, 2026phase 0 trial completion85d agoUniversity of Southern California — methylprednisolone (Phase 0 Trial Completion)MEDROL

Therapy area: Immunology. Indication: Drug Hypersensitivity Reactions

full page →MEDROL →source: globaldata
›Apr 30, 2026phase 1 completion85d agoDongguan Traditional Chinese Medicine Hospital — undisclosed traditional Chinese medicine (Phase I Trial Completion)undisclosed traditional Chinese medicine

Therapy area: Immunology, Musculoskeletal Disorders. Indication: Osteoporosis, Rheumatoid Arthritis, Sarcopenia

full page →undisclosed traditional Chinese medicine →source: globaldata
›Apr 30, 2026phase 1 completion85d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →CIGB-814 →source: globaldata
›Apr 30, 2026phase 1 completion85d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

full page →(acetaminophen + ibuprofen) →source: globaldata
›Apr 30, 2026phase 1 completion85d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata
›Apr 30, 2026phase 1 completion85d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata
›Apr 30, 2026phase 1 completion85d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

full page →HLK-0006 →source: globaldata
›Apr 30, 2026phase 1 initiation85d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata
›Apr 30, 2026phase 2 completion85d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata
›Apr 30, 2026phase 2 completion85d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata
›Apr 30, 2026phase 2 completion85d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata
›Apr 30, 2026phase 2 completion85d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata
›Apr 30, 2026phase 2 completion85d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata
›Apr 30, 2026phase 2 completion85d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata
›Apr 30, 2026phase 2 completion85d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata
$FTRE18.49+3.24%
$MRK130.13+2.08%
$ECL266.88+1.01%